Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study

Abstract

Pretreatment with either oxybutynin or tolterodine reduces the incidence and severity of catheter related bladder discomfort.

The effect of sevoflurane versus desflurane on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of a bladder tumour: a randomized controlled trial

“…This finding suggests that sevoflurane and desflurane inhalation, regardless of the chosen inhalation agent, showed fewer antimuscarinic side effects compared with antimuscarinic agents used for CRBD treatment in previous studies. 1,8,19 In our investigation, the overall incidence of CRBD was 41/44 (93%) patients in the desflurane group. The incidence of CRBD has been reported to be 58-71%.…”

“…17 In previous studies, various agents with antimuscarinic properties, such as gabapentin, oxybutynin, tolterodine, and tramadol, were found to reduce the incidence and severity of postoperative CRBD. 1,2,[7][8][9][18][19][20] In this study, use of sevoflurane resulted in a greater reduction in the incidence of CRBD when compared with desflurane by 24%, 33%, and 26% at zero, one, and six hours after surgery, respectively. This preventive effect of sevoflurane on CRBD is similar to that of antimuscarinic agents reported in previous studies in which tolterodine and gabapentin reduced the incidence of CRBD by 19-30% until six hours postoperatively.…”

“…The incidence of CRBD has been reported to be 58-71%. 8,9,19 The relatively high incidence of CRBD in this study is related to TURBT. In patients undergoing TURBT, the bladder mucosa is electrically cauterized and a large Foley catheter is introduced postoperatively.…”

“…1,18 The use of antimuscarinic agents for the treatment of CRBD increased the incidence of postoperative side effects, including dry mouth, nausea, vomiting, and sedation. 1,7,8,18,19 For example, the use of antimuscarinic agents tolterodine and oxybutynin increased the incidence of dry mouth (59%), while the use of tramadol increased the incidences of sedation (92%), nausea (56%), and vomiting (40%). 1,8,19 In this study, the incidences of dry mouth, nausea, and vomiting were within 10% in both the sevoflurane and desflurane groups during the entire study period.…”

“…1,7,8,18,19 For example, the use of antimuscarinic agents tolterodine and oxybutynin increased the incidence of dry mouth (59%), while the use of tramadol increased the incidences of sedation (92%), nausea (56%), and vomiting (40%). 1,8,19 In this study, the incidences of dry mouth, nausea, and vomiting were within 10% in both the sevoflurane and desflurane groups during the entire study period. This finding suggests that sevoflurane and desflurane inhalation, regardless of the chosen inhalation agent, showed fewer antimuscarinic side effects compared with antimuscarinic agents used for CRBD treatment in previous studies.…”